Literature DB >> 34053450

Cardiovascular magnetic resonance detects microvascular dysfunction in a mouse model of hypertrophic cardiomyopathy.

Min-Chi Ku1,2, Frank Kober3, Yi-Ching Lai4, Andreas Pohlmann4, Fatimunnisa Qadri5, Michael Bader6,5, Lucie Carrier7,8, Thoralf Niendorf4,6,9.   

Abstract

BACKGROUND: Hypertrophic cardiomyopathy (HCM) related myocardial vascular remodelling may lead to the reduction of myocardial blood supply and a subsequent progressive loss of cardiac function. This process has been difficult to observe and thus their connection remains unclear. Here we used non-invasive myocardial blood flow sensitive CMR to show an impairment of resting myocardial perfusion in a mouse model of naturally occurring HCM.
METHODS: We used a mouse model (DBA/2 J; D2 mouse strain) that spontaneously carries variants in the two most susceptible HCM genes-Mybpc3 and Myh7 and bears the key features of human HCM. The C57BL/6 J (B6) was used as a reference strain. Mice with either B6 or D2 backgrounds (male: n = 4, female: n = 4) underwent cine-CMR for functional assessment at 9.4 T. Left ventricular (LV) wall thickness was measured in end diastolic phase by cine-CMR. Quantitative myocardial perfusion maps (male: n = 5, female: n = 5 in each group) were acquired from arterial spin labelling (cine ASL-CMR) at rest. Myocardial perfusion values were measured by delineating different regions of interest based on the LV segmentation model in the mid ventricle of the LV myocardium. Directly after the CMR, the mouse hearts were removed for histological assessments to confirm the incidence of myocardial interstitial fibrosis (n = 8 in each group) and small vessel remodelling such as vessel density (n = 6 in each group) and perivascular fibrosis (n = 8 in each group).
RESULTS: LV hypertrophy was more pronounced in D2 than in B6 mice (male: D2 LV wall thickness = 1.3 ± 0.1 mm vs B6 LV wall thickness = 1.0 ± 0.0 mm, p < 0.001; female: D2 LV wall thickness = 1.0 ± 0.1 mm vs B6 LV wall thickness = 0.8 ± 0.1 mm, p < 0.01). The resting global myocardial perfusion (myocardial blood flow; MBF) was lower in D2 than in B6 mice (end-diastole: D2 MBFglobal = 7.5 ± 0.6 vs B6 MBFglobal = 9.3 ± 1.6 ml/g/min, p < 0.05; end-systole: D2 MBFglobal = 6.6 ± 0.8 vs B6 MBFglobal = 8.2 ± 2.6 ml/g/min, p < 0.01). This myocardial microvascular dysfunction was observed and associated with a reduction in regional MBF, mainly in the interventricular septal and inferior areas of the myocardium. Immunofluorescence revealed a lower number of vessel densities in D2 than in B6 (D2 capillary = 31.0 ± 3.8% vs B6 capillary = 40.7 ± 4.6%, p < 0.05). Myocardial collagen volume fraction (CVF) was significantly higher in D2 LV versus B6 LV mice (D2 CVF = 3.7 ± 1.4% vs B6 CVF = 1.7 ± 0.7%, p < 0.01). Furthermore, a higher ratio of perivascular fibrosis (PFR) was found in D2 than in B6 mice (D2 PFR = 2.3 ± 1.0%, B6 PFR = 0.8 ± 0.4%, p < 0.01).
CONCLUSIONS: Our work describes an imaging marker using cine ASL-CMR with a potential to monitor vascular and myocardial remodelling in HCM.

Entities:  

Keywords:  Arterial spin labelling (ASL); Cardiac MRI (CMR); Hypertrophic cardiomyopathy (HCM); Microvascular dysfunction; Myocardial blood flow (MBF); Myocardial remodelling; Perfusion

Year:  2021        PMID: 34053450     DOI: 10.1186/s12968-021-00754-z

Source DB:  PubMed          Journal:  J Cardiovasc Magn Reson        ISSN: 1097-6647            Impact factor:   5.364


  61 in total

Review 1.  Hypertrophic cardiomyopathy.

Authors:  Barry J Maron; Martin S Maron
Journal:  Lancet       Date:  2012-08-06       Impact factor: 79.321

2.  Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin.

Authors:  Christopher N Toepfer; Hiroko Wakimoto; Amanda C Garfinkel; Barbara McDonough; Dan Liao; Jianming Jiang; Angela C Tai; Joshua M Gorham; Ida G Lunde; Mingyue Lun; Thomas L Lynch; James W McNamara; Sakthivel Sadayappan; Charles S Redwood; Hugh C Watkins; Jonathan G Seidman; Christine E Seidman
Journal:  Sci Transl Med       Date:  2019-01-23       Impact factor: 17.956

Review 3.  Cardiomyopathies: from genetics to the prospect of treatment.

Authors:  W M Franz; O J Müller; H A Katus
Journal:  Lancet       Date:  2001-11-10       Impact factor: 79.321

Review 4.  Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine.

Authors:  Barry J Maron; Steve R Ommen; Christopher Semsarian; Paolo Spirito; Iacopo Olivotto; Martin S Maron
Journal:  J Am Coll Cardiol       Date:  2014-07-08       Impact factor: 24.094

Review 5.  New perspectives on the prevalence of hypertrophic cardiomyopathy.

Authors:  Christopher Semsarian; Jodie Ingles; Martin S Maron; Barry J Maron
Journal:  J Am Coll Cardiol       Date:  2015-03-31       Impact factor: 24.094

6.  Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers.

Authors:  Michelle Michels; Osama I I Soliman; Judith Phefferkorn; Yvonne M Hoedemaekers; Marcel J Kofflard; Dennis Dooijes; Danielle Majoor-Krakauer; Folkert J Ten Cate
Journal:  Eur Heart J       Date:  2009-08-06       Impact factor: 29.983

Review 7.  Pathological ventricular remodeling: mechanisms: part 1 of 2.

Authors:  Jana S Burchfield; Min Xie; Joseph A Hill
Journal:  Circulation       Date:  2013-07-23       Impact factor: 29.690

8.  Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006.

Authors:  Barry J Maron; Joseph J Doerer; Tammy S Haas; David M Tierney; Frederick O Mueller
Journal:  Circulation       Date:  2009-02-16       Impact factor: 29.690

9.  A Prospective Study of Sudden Cardiac Death among Children and Young Adults.

Authors:  Richard D Bagnall; Robert G Weintraub; Jodie Ingles; Johan Duflou; Laura Yeates; Lien Lam; Andrew M Davis; Tina Thompson; Vanessa Connell; Jennie Wallace; Charles Naylor; Jackie Crawford; Donald R Love; Lavinia Hallam; Jodi White; Christopher Lawrence; Matthew Lynch; Natalie Morgan; Paul James; Desirée du Sart; Rajesh Puranik; Neil Langlois; Jitendra Vohra; Ingrid Winship; John Atherton; Julie McGaughran; Jonathan R Skinner; Christopher Semsarian
Journal:  N Engl J Med       Date:  2016-06-23       Impact factor: 91.245

10.  Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes.

Authors:  Jodie Ingles; Jennifer Goldstein; Courtney Thaxton; Colleen Caleshu; Edward W Corty; Stephanie B Crowley; Kristen Dougherty; Steven M Harrison; Jennifer McGlaughon; Laura V Milko; Ana Morales; Bryce A Seifert; Natasha Strande; Kate Thomson; J Peter van Tintelen; Kathleen Wallace; Roddy Walsh; Quinn Wells; Nicola Whiffin; Leora Witkowski; Christopher Semsarian; James S Ware; Ray E Hershberger; Birgit Funke
Journal:  Circ Genom Precis Med       Date:  2019-02
View more
  1 in total

1.  Capillaries as a Therapeutic Target for Heart Failure.

Authors:  Yohko Yoshida; Ippei Shimizu; Tohru Minamino
Journal:  J Atheroscler Thromb       Date:  2022-04-01       Impact factor: 4.394

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.